Wedbush cuts Geron stock price target to $5 on study halt

Wedbush cut its Geron price target to $5 from $6 after the company discontinued the IMpactMF study, removing about $130 million in modeled sales at the 2028 valuation date, but retained an Outperform rating and said there were no new safety signals or meaningful change to Rytelo’s commercial outlook. Rytelo generated $57.5 million in Q2 2026 revenue, up 17% year over year and 11% sequentially, while management pointed to the mid-to-high end of its $220 million–$240 million full-year guidance. Adjusted EPS was a 2-cent loss versus the expected 1-cent loss.

Analysis

The discontinuation removes a material piece of long-dated optionality; it does not by itself establish that imetelstat’s biology failed. The market question is whether the remaining Rytelo franchise can finance development and eventually offset the lost program value without repeated equity issuance. Account growth is encouraging, but it is not the same as durable patient starts or improved unit economics: monitor prescriptions, persistence, gross-to-net, and cash burn alongside revenue. In lower-risk MDS, continued uptake also depends on treatment sequencing against established options such as ESAs and Bristol Myers Squibb’s Reblozyl, not just guideline positioning.

Near term, the study news may keep sentiment and volatility weak; over 1–3 months, quarterly Rytelo demand and any IST data are the key checks on the commercial-plus-pipeline thesis. Over 6–18 months, financing runway and evidence that Rytelo growth can support the business matter more than an analyst target. Contrarian angle: the selloff may over-discount the lost 2028 opportunity if commercial execution persists, but a low share price is not evidence of undervaluation. The article’s quoted price and 52-week-low comparison are internally inconsistent; verify market data and corporate actions before sizing.

Key Decisions for Investors

• Avoid treating the price-target reduction as a standalone signal or using the target as fair value. Before taking exposure, verify cash, quarterly cash burn, debt, and likely funding needs; these determine whether Rytelo growth accrues to shareholders or is diluted.
• Watchlist, not an automatic long: consider a small, risk-defined long only after confirming the next quarter sustains prescription/account growth and provides evidence on patient persistence and cash runway. Falsification: a material slowdown in Rytelo demand, weaker guidance, or a sharp deterioration in cash runway.
• Treat upcoming IST readouts as event risk rather than base-case value until study design, enrollment, timing, and endpoints are verified. Positive data could restore some pipeline optionality; negative or delayed data would leave valuation more dependent on one commercial product.
• No compelling pair trade from this information alone. Track Rytelo uptake and relevant MDS treatment alternatives, including Reblozyl and ESAs, for signs of substitution or sequencing pressure before positioning against competitors.